ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2011
Neuroimaging in dementia.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 5 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- Utilisation of brain MRI for the diagnosis of dementia in low and middle-income countries: systematic review and meta-analysis.BMJ open · 2026Pooled it
- Effects of different interventions based on virtual reality on cognitive and motor function in elderly people with mild cognitive impairment or dementia: a systematic review and network meta-analysis.Frontiers in aging neuroscience · 2026Pooled it
- Correlates of Functional Impairment in Patients with the Behavioral Variant of Frontotemporal Dementia: A PRISMA-Compliant Systematic Review.International journal of molecular sciences · 2023Pooled it
- Systematic review of the diagnostic utility of SPECT imaging in dementia.European archives of psychiatry and clinical neuroscience · 2013Pooled it
- Diagnostic criteria for vascular cognitive disorders: a VASCOG statement.Alzheimer disease and associated disordersGuideline
- Brain-Derived neurotrophic factor and inflammatory biomarkers are unaffected by acute and chronic intermittent hypoxic-hyperoxic exposure in geriatric patients: a randomized controlled trial.Annals of medicine · 2024Trial
- Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019Trial
- Free water, occipital volume and changes in depressive symptoms in the LifeAfter90 study.Scientific reports · 2026Article
- AI-powered evaluation of dementia severity based on clinical data and visual scoring systems (MTA, ERICA, GCA) from MRI.Scientific reports · 2026Article
- Explainable machine learning identifies candidate shared neuroanatomical features in Alzheimer's and Parkinson's via importance inversion transfer.bioRxiv : the preprint server for biology · 2026Article
- Mapping the clinical correlates of brain hypoperfusion in behavioral variant frontotemporal dementia: insights from a SPECT imaging study.Frontiers in neuroscience · 2026Article
- Advances in AI-based diagnosis of Alzheimer's disease using MRI: a comprehensive survey.Frontiers in medicine · 2026Review
- Article
- CT-derived brain volumes and plasma p-Tau217 for risk stratification of amyloid positivity in early-stage Alzheimer's disease.Alzheimer's research & therapy · 2025Article
- Integrating MRI Volume and Plasma p-Tau217 for Amyloid Risk Stratification in Early-Stage Alzheimer Disease.Neurology · 2025Article
- Developing an accessible dementia assessment tool: Leveraging a residual network, the trail making test, and demographic data.Journal of Alzheimer's disease : JAD · 2025Article
- Depressive symptoms are associated with hippocampal volume in the oldest-old: The LifeAfter90 study.Psychiatry research. Neuroimaging · 2025Article
- In vivo effect of LATE-NC on integrity of white matter connections to the hippocampus.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Development of a robust parallel and multi-composite machine learning model for improved diagnosis of Alzheimer's disease: correlation with dementia-associated drug usage and AT(N) protein biomarkers.Frontiers in neuroscience · 2024Article
- A multi-site, multi-participant magnetoencephalography resting-state dataset to study dementia: The BioFIND dataset.NeuroImage · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Dementia is a common illness with an incidence that is rising as the aged population increases. There are a number of neurodegenerative diseases that cause dementia, including Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia, which is subdivided into the behavioral variant, the semantic variant, and nonfluent variant. Numerous other neurodegenerative illnesses have an associated dementia, including corticobasal degeneration, Creutzfeldt-Jakob disease, Huntington's disease, progressive supranuclear palsy, multiple system atrophy, Parkinson's disease dementia, and amyotrophic lateral sclerosis. Vascular dementia and AIDS dementia are secondary dementias. Diagnostic criteria have relied on a constellation of symptoms, but the definite diagnosis remains a pathologic one. As treatments become available and target specific molecular abnormalities, differentiating amongst the various primary dementias early on becomes essential. The role of imaging in dementia has traditionally been directed at ruling out treatable and reversible etiologies and not to use imaging to better understand the pathophysiology of the different dementias. Different brain imaging techniques allow the examination of the structure, biochemistry, metabolic state, and functional capacity of the brain. All of the major neurodegenerative disorders have relatively specific imaging findings that can be identified. New imaging techniques carry the hope of revolutionizing the diagnosis of neurodegenerative disease so as to obtain a complete molecular, structural, and metabolic characterization, which could be used to improve diagnosis and to stage each patient and follow disease progression and response to treatment. Structural and functional imaging modalities contribute to the diagnosis and understanding of the different dementias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.